Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to ...
Janos L. Tanyi, MD, PhD, of Penn Medicine, shared an early report of a new type of CAR T cell therapy, called KIR-CAR, in a Clinical Trial Plenary session at the AACR Annual Meeting 2026.
A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in ...
MedPage Today on MSN
CAR-T trial raises prospect of preventing myeloma in high-risk group
All 20 smoldering myeloma patients had deep responses after one-time infusion ...
Cancers that were once considered incurable now have new treatment options. Among these innovations are CAR-T (chimeric ...
A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, ...
IFLScience on MSN
CAR-T therapy is revolutionizing cancer treatment. Next on the list: autoimmune disease
A woman who had been sick for many years with three autoimmune conditions has experienced a remarkable recovery after being ...
A single-center real-world study compares the effectiveness and toxicity of chimeric antigen receptor T-cell therapy vs ...
CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...
Doctors at the University of Washington and Fred Hutch Cancer Center have better characterized an emerging complication of chimeric antigen receptor (CAR) T-cell therapy. A recent paper in Movement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results